| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 7, 2011New Structure Uniquely Positions Medtronic to Maintain Focus on Clinicians While Addressing the Needs of Cardiac and Vascular-focused Hospital Administrators
MINNEAPOLIS, Apr 07, 2011 (BUSINESS WIRE) -- Responding to the challenges hospitals face in the changing healthcare environment, as well as the increasing importance of the hospital administrator...
-
Apr 4, 2011Across Spectrum of Patients with Coronary Artery Disease, Novel Heart Device Shows Strong Results at One Year in RESOLUTE US and Two Years in RESOLUTE All Comers
NEW ORLEANS, Apr 04, 2011 (BUSINESS WIRE) -- Results of two major clinical studies presented at ACC.11 - the 60th Annual Scientific Session & Expo of the American College of Cardiology (ACC) -...
-
Apr 4, 2011Software Helps Users Identify Low and High Glucose Levels
MINNEAPOLIS, Apr 04, 2011 (BUSINESS WIRE) -- Medtronic, Inc. today announced the Food and Drug Administration (FDA) approval and the market launch of CareLink(R) Personal 5.4 Therapy Management...
-
Apr 4, 2011Study Published Today in Circulation is the First to Assess the Correlation of Seven Heart Failure Process-Based Quality Measures with Clinical Outcomes
MINNEAPOLIS, Apr 04, 2011 (BUSINESS WIRE) -- Results from the largest U.S. outpatient heart failure clinical study, published today in the journal Circulation and funded by Medtronic, Inc. (NYSE:...
-
Apr 1, 2011Unique Sacral Nerve Stimulation Therapy Now Available for Treatment of Chronic Fecal Incontinence
MINNEAPOLIS, Apr 01, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of InterStim(R) Therapy for Bowel Control. InterStim...
-
Mar 28, 2011Late-Breaking Clinical Trials Feature One-Year Results of RESOLUTE US Study; Latest Evidence from Comprehensive Research Program Completes FDA Approval Submission
MINNEAPOLIS, Mar 28, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), today announced the imminent release of the pivotal U.S. data on its Resolute(R) drug-eluting stent (DES) at ACC.11, the 60th
-
Mar 28, 2011New Implantable Cardiac Devices with SmartShock(TM) Technology Enhance Patient Quality of Life
MINNEAPOLIS, Mar 28, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Protecta(TM)portfolio of implantable...
-
Mar 24, 2011CRT Innovation is the First to Offer Exclusive OptiVol(R) Fluid Status Monitoring with Complete Remote Follow-Up for Proactive Heart Failure Management
MINNEAPOLIS, Mar 24, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food & Drug Administration (FDA) has approved its Consulta(R) and Syncra(TM) cardiac...
-
Mar 16, 2011Single-Channel Device Completes Medtronic's Advanced Activa(R) Therapy Portfolio for Patients with Movement Disorders
MINNEAPOLIS, Mar 16, 2011 (BUSINESS WIRE) -- With the first U.S. implant of its new Activa SC neurostimulator for deep brain stimulation (DBS) therapy, Medtronic, Inc. (NYSE: MDT) today announced...
-
Mar 14, 2011NewRemodeling Ring Enhances Medtronic's Surgical Heart Valve Repair Portfolio
MINNEAPOLIS, Mar 14, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced the global launch of a new tricuspid ring for the treatment of tricuspid valve disease. Called the Contour...